Introduction Immune checkpoint inhibitors are active in advanced cervical cancer. SKYSCRAPER-04 (NCT04300647) evaluated dual blockade with tiragolumab (anti-TIGIT) and atezolizumab (anti-PD-L1) (tira+atezo), an approach hypothesized to overcome immune suppression and restore immune response.
Methods Eligible patients had measurable (per investigator assessment) PD-L1-positive recurrent/persistent cervical cancer after 1–2 prior chemotherapy lines (including ≥1 platinum-based regimen). Patients were randomized 3:1 to atezolizumab 1200 mg with or without tiragolumab 600 mg q3w until unacceptable toxicity/progression. Crossover to tira+atezo was permitted after unequivocal progression during single-agent atezolizumab. Stratification factors were ECOG PS, prior (chemo)radiotherapy, and disease status. The primary endpoint was independent review committee (IRC)-assessed confirmed objective response rate (ORR) per RECIST v1.1 in all treated patients randomized to tira+atezo. An ORR ≥21% (1-sample z-test p≤0.0245) was required to demonstrate statistically significant improvement versus a 14.6% historical reference [Chung, 2019]. Secondary endpoints included IRC-assessed progression-free survival, overall survival, and pre-crossover safety.
Results Prior therapy in 171 treated patients included bevacizumab in 35%, (chemo)radiotherapy in 80%, and paclitaxel in 93%. IRC-assessed ORRs were 19.0% with tira+atezo and 15.6% with atezo alone (table 1). In post hoc exploratory analyses of patients with measurable disease per IRC assessment, ORRs were 21.6% (tira+atezo) and 15.8% (atezo). There were no new safety signals. In a post hoc follow-up analysis, 15% of patients remained on treatment and 15/45 initially randomized to atezo had crossed over to tira+atezo.
Conclusion/Implications The ORR with tira+atezo was numerically but not significantly higher than the historical benchmark. This is the first reported phase 2 cervical cancer trial targeting TIGIT and PD-L1 concurrently.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.